
Press Release

October 30, 2024

Sumitomo Pharma Co., Ltd.

Notice Concerning Finance Costs

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; Securities Code: 4506, Prime Market of TSE) announced today that it recorded finance costs for the second quarter of the fiscal year ending March 31, 2025 (from April 1, 2024 to September 30, 2024) as follows.

1. Details of Finance Costs

The Company recorded a foreign exchange loss of 21,479 million yen under finance costs for the six months ended September 30, 2024 due to recent fluctuations in foreign exchange rates. This was mainly due to the valuation of foreign currency-denominated liabilities held by its overseas subsidiaries.

In addition, foreign exchange loss of 43,007 million yen was recorded in the three months ended September 30, 2024, because financial income (foreign exchange gain) of 21,528 million yen was recorded in the three months ended June 30, 2024.

2. Future Outlook

Regarding the impact of the above finance costs on the results of the Company operations, please refer to the “Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2025 [IFRS]” announced today. Since the amount will fluctuate depending on the future foreign exchange rates, the Company has not revised the financial forecasts at this time.

Contact:

Corporate Communications

Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp.